We are live on ! Find out more

FEED

ENVUE MEDICAL INC NEW

FEED

Delisted

FEED was delisted on the 15th of September, 2026.

Back to rankings

About: ENVUE MEDICAL INC NEW

Healthcare Medical Devices

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 10%

Neutral 90%

Negative 0%

ENvue Medical Provides Nasdaq Listing Update

TYLER, Texas, Sept. 15, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (Nasdaq: FEED) (“ENvue” or the “Company”), a medical technology company focused on innovative solutions for enteral feeding and therapeutic ultrasound, today announced that it has received a decision from the Nasdaq Hearings Panel (the “Panel”) denying the Company's request for continued listing on The Nasdaq Capital Market. As a result, trading of the Company's common stock will be suspended and will begin trading on the OTC Markets under the same stock symbol, ‘FEED', on September 16, 2026.

ENvue Medical Provides Nasdaq Listing Update

ENvue Medical Resumes U.S. Commercial Shipments of NanoVibronix PainShield® and Begins Fulfilling Open Distributor Orders

TYLER, Texas, Sept. 09, 2026 (GLOBE NEWSWIRE) -- ENvue Medical , Inc. (NASDAQ: FEED) (“ENvue” or the “Company”), a commercial-stage medical device company focused on real-time guided bedside feeding tube placement and therapeutic technologies, today announced that it has resumed commercial shipments of PainShield®, manufactured in the United States, and has begun fulfilling open orders from Ultra Pain Products, Inc. (“UPPI”), the Company's exclusive U.S. distribution partner for the product.

ENvue Medical Resumes U.S. Commercial Shipments of NanoVibronix PainShield® and Begins Fulfilling Open Distributor Orders

ENvue Medical Selected to Exhibit ENvue™ Navigation Platform at Vizient Innovative Technology Exchange

TYLER, Texas, Sept. 02, 2026 (GLOBE NEWSWIRE) -- ENvue Medical (NASDAQ: FEED) (“ENvue” or the “Company”), a commercial-stage medical device company focused on real-time guided bedside feeding tube placement, today announced it has been selected to exhibit its ENvue™ Navigation Platform, a minimally invasive electromagnetic navigation system guiding feeding tube placement, at the Vizient® Innovative Technology Exchange.

ENvue Medical Selected to Exhibit ENvue™ Navigation Platform at Vizient Innovative Technology Exchange

ENvue Medical Announces Exclusive UroShield® Distribution Agreement with Minimum Purchase Commitments of Approximately $2.6 Million

Multi-year agreement with Peak Medical expands UroShield commercialization across the United Kingdom and Republic of Ireland Multi-year agreement with Peak Medical expands UroShield commercialization across the United Kingdom and Republic of Ireland

ENvue Medical Announces Exclusive UroShield® Distribution Agreement with Minimum Purchase Commitments of Approximately $2.6 Million

ENvue Medical Secures Equity Financing Facility of Up to $50 Million to Support Commercial Growth, Technology Expansion and Strategic Acquisitions

TYLER, Texas, Aug. 12, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ: FEED) ("ENvue" or the "Company"), a commercial-stage medical technology company, today announced that it has entered into a securities purchase agreement (“ELOC”) with an institutional investor providing the Company with an equity facility for up to $50 million in capital (the “Facility”), subject to the terms and conditions of the agreement, including the receipt of stockholder approval.

ENvue Medical Secures Equity Financing Facility of Up to $50 Million to Support Commercial Growth, Technology Expansion and Strategic Acquisitions

ENvue Medical Moves NanoVibronix Manufacturing to the United States, Consolidates R&D in Tel Aviv, Israel, Increasing Operational Efficiencies and Cost Reduction Opportunities

TYLER, Texas, Aug. 04, 2026 (GLOBE NEWSWIRE) -- ENvue Medical , Inc. (NASDAQ: FEED) (“ENvue” or the “Company”), a commercial-stage medical device company, today announced it has completed the transition of its NanoVibronix manufacturing operations from Israel to the United States, and consolidated its research and development operations in Tel Aviv, Israel, supporting the Company's broader initiative to reduce operating expenses and improve its cost structure. “Completing the transition of our NanoVibronix product line manufacturing to the United States marks the achievement of a major strategic operational initiative for the Company,” said Doron Besser, MD, CEO of ENvue Medical.

ENvue Medical Moves NanoVibronix Manufacturing to the United States, Consolidates R&D in Tel Aviv, Israel, Increasing Operational Efficiencies and Cost Reduction Opportunities

ENvue Medical Deploys Additional Navigation Platform with Existing Customer, A Leading North Texas Medical Center

Additional Platform Deployment at Major Academic Medical Center Reflects Increasing Commercial Demand for Bedside Feeding Tube Navigation Additional Platform Deployment at Major Academic Medical Center Reflects Increasing Commercial Demand for Bedside Feeding Tube Navigation

ENvue Medical Deploys Additional Navigation Platform with Existing Customer, A Leading North Texas Medical Center

ENvue Medical Appoints Chairman of the Board and New Directors, Bringing Clinical, AI Governance and Capital Markets Expertise to Navigation Platform

Zeev Rotstein, M.D. Named Chairman Following Four Decades in Health System Leadership, Including 12 Years as Director General of Sheba Medical Center Zvi Joseph and Lior Buchman Join Board, Bringing Amdocs AI Governance Leadership and $320 Million in Executed Financings and M&A, Respectively TYLER, Texas, July 15, 2026 (GLOBE NEWSWIRE) -- ENvue Medical (NASDAQ: FEED) (“ENvue,” “ENvue Medical” or the “Company”), a commercial-stage medical device company focused on real-time guided bedside feeding tube placement, today announced that Zeev Rotstein, M.D.

ENvue Medical Appoints Chairman of the Board and New Directors, Bringing Clinical, AI Governance and Capital Markets Expertise to Navigation Platform

Envue Medical Expands AI Navigation Platform With Robotic Prototype

ENvue Medical, Inc. (NASDAQ:FEED) announced Thursday the development and demonstration of the prototype of ENvue Drive.

Envue Medical Expands AI Navigation Platform With Robotic Prototype

ENvue Medical Unveils Its First Robotic-Assisted, Artificial Intelligence, Feeding Tube Automation Tool

ENvue Targeting Combined $10 Billion+ Enteral Feeding and Vascular Access Market Opportunity* ENvue Drive™ Demonstration Marks First Step Toward a New Generation of Intelligent Bedside Procedures and Integrates ENvue's Proprietary AI Navigation Software, Ask Oscar™ TYLER, Texas, July 09, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ: FEED) (“ENvue,” “ENvue Medical” or the “Company”), a commercial-stage medical device company focused on real-time guided bedside feeding tube placement, today announced the successful development and demonstration of the first prototype of ENvue Drive™, which the Company believes is the first next-generation robotic-assisted tool built within the ENvue electromagnetic navigation platform ecosystem, designed to integrate artificial intelligence, real-time navigation, and robotic-assisted procedural execution into a unified clinical workflow. A demonstration video highlighting the ENvue Drive prototype, including integrated navigation, artificial intelligence, and robotic-assisted advancement capabilities, is available here: http://envue.com/ask-oscar/#video.

ENvue Medical Unveils Its First Robotic-Assisted, Artificial Intelligence, Feeding Tube Automation Tool

See News Rankings

Price charts implemented using Lightweight Charts™